Iterum Therapeutics (ITRM) Scheduled to Post Earnings on Thursday

Iterum Therapeutics (NASDAQ:ITRMGet Rating) is scheduled to be releasing its earnings data before the market opens on Thursday, March 16th. Analysts expect Iterum Therapeutics to post earnings of ($1.22) per share for the quarter.

Iterum Therapeutics Stock Performance

Iterum Therapeutics stock opened at $1.01 on Tuesday. The stock’s 50 day simple moving average is $1.19 and its two-hundred day simple moving average is $1.47. The company has a debt-to-equity ratio of 0.29, a quick ratio of 8.88 and a current ratio of 8.88. The stock has a market cap of $12.34 million, a price-to-earnings ratio of -0.28 and a beta of 1.63. Iterum Therapeutics has a fifty-two week low of $0.60 and a fifty-two week high of $7.05.

Institutional Trading of Iterum Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC lifted its position in Iterum Therapeutics by 199.1% in the 2nd quarter. Renaissance Technologies LLC now owns 323,300 shares of the company’s stock valued at $65,000 after acquiring an additional 215,200 shares in the last quarter. Goldman Sachs Group Inc. purchased a new stake in shares of Iterum Therapeutics in the 2nd quarter worth $61,000. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of Iterum Therapeutics in the 3rd quarter worth $101,000. 2.60% of the stock is owned by institutional investors.

Iterum Therapeutics Company Profile

(Get Rating)

Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous branded penem available. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.

Read More

Earnings History for Iterum Therapeutics (NASDAQ:ITRM)

Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with's FREE daily email newsletter.